IR-902 is under clinical development by Immune Response BioPharma and currently in Phase III for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Phase III drugs for Secondary Progressive Multiple Sclerosis (SPMS) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how IR-902’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IR-902 overview
IR-902 (NeuroVax) is under development for the treatment of secondary progressive multiple sclerosis. It is administered by intramuscular route. The vaccine candidate is based on FOXP3+ expression technology. It is a synthetic T cell receptor (TCR) peptide comprising contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-cells. It was under development for the treatment of pediatric multiple sclerosis.
See Also:
Immune Response BioPharma overview
Immune Response BioPharma is a company that discovers and develops vaccines and drugs for auto-immune and infectious diseases. The company is headquartered in Atlantic City, New Jersey, the US.
For a complete picture of IR-902’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
